Patient-derived α-synuclein seed amplification as a tool for evaluating small molecule aggregation inhibitors for Parkinson’s disease and Lewy Body Dementia therapeutics
Objective: To validate on-target engagement of disease-relevant ⍺-synuclein (a-syn) aggregates by WTX-607, WaveBreak’s small-molecule clinical candidate for Parkinson’s disease (PD) and Lewy body dementia (LBD),…The Movement Disorders Society Unified Parkinson Disease Rating Scale Motor Subscore Is Not Associated With Future Parkinson Disease Milestones – an observational study using linked health administrative data
Objective: To examine the association between time to Parkinson Disease (PD) health administrative data milestones and a one-year change in the Movement Disorders Society –…Plasma P-tau217 detects Alzheimer’s co-pathology and predicts cognitive decline in Parkinson’s disease
Objective: The objectives of this study are to compare plasma phosphorylated tau-217 (P-tau217) levels in Parkinson’s disease (PD) with versus without Alzheimer’s disease (AD) copathology…Multimodal Dissection of GALC Variants Linking Olfactory Deficits to Cognitive Decline in Parkinson’s Disease
Objective: Olfactory dysfunction is highly prevalent and often precedes motor symptoms, making it a potential early biomarker for disease progression and cognitive decline in Parkinson's…Metabolomics Profiling in Egyptian Patients with Alzheimer’s and Parkinson’s Diseases
Objective: To identify differential serum metabolites found in AD and PD patients and their correlations to clinical presentation in Egyptian patients. Background: There is a…Neurodegeneration Biomarkers: Correlation between Hippocampal Volume and Cognitive Performance by MoCA Test in Parkinson’s Disease
Objective: This study aims to examine the relationship between hippocampal volume, assessed through magnetic resonance imaging (MRI), and MoCA test scores in patients diagnosed with…Sex Differences for Autopsy-Confirmed Prodromal Lewy Body Dementia
Objective: To assess sex differences in prodromal Lewy body dementia (LBD) compared to Alzheimer’s disease (AD) Background: Identifying LBD at the prodromal stage can provide…Association between cognitive adverse effects of anticholinergic medication and development of long-term dementia in Parkinson’s disease
Objective: To investigate whether cognitive adverse effects occurring immediately after taking anticholinergics are related to the development of long-term dementia and to interpret this from…Comparative Analysis of MoCA Scores Between Latin American Latinos and White Patients with Parkinson’s Disease
Objective: The study objectives were to 1) characterize scores on the Montreal Cognitive Assessment (MoCA) in patients with Parkinson’s disease (PD) from Latin America, 2)…Preoperative Predictors of Post-DBS Cognitive Decline: Cardiac MIBG Imaging and Levodopa Burden as Risk Factors for Dementia in Parkinson’s Disease
Objective: To identify preoperative clinical and imaging predictors of post-deep brain stimulation (DBS) dementia in Parkinson's disease (PD) patients, focusing on multiple potential risk factors…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 36
- Next Page »